9/18/18 · GeneQuine licensed this technology from Baylor in the early stages and was able to develop it further and attract the interest of Flexion Therapeutics, which acquired the program for application in patients and plans to take the therapy to the clinical setting next year, pending successful GLP(good laboratory practice) toxicology studies3 GeneQuine Biotherapeutics GmbH, Hamburg, Germany 4 Baylor College of Medicine, Houston, Texas, and GeneQuine Biotherapeutics GmbH, Hamburg, Germany PMID1/26/21 · Supports Development of Promising Gene Therapy Platform for OsteoarthritisPARSIPPANY, NJ, Jan 26, 21 (GLOBE NEWSWIRE) Pacira BioSciences, Inc (Nasdaq PCRX), the leading provider of innovative nonopioid pain management options, today announced that the company will lead an equity investment in GeneQuine Biotherapeutics
Nicole Suchier Science Communication Hamburg Home Facebook
Reinaldo janequine